Veterinary Oncology Market
Veterinary Oncology Market Analysis by Radiology, Chemotherapy, Combination Therapy, Immunotherapy, and Targeted Therapy from 2023 to 2033
Analysis of Veterinary Oncology Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Veterinary Oncology Market Overview (2023 to 2033)
The global veterinary oncology market size stands at a valuation of US$ 260 Million in 2023, and is estimated to reach US$ 800 Million by 2033-end, with a projected compound annual growth rate (CAGR) of 12% during the forecast period from 2023 to 2033.
Veterinary oncology constitutes a specialized field within veterinary medicine, focusing on the diagnosis and treatment of cancer in animals. Among pet animals, cancer stands as a significant contributor to mortality. In a veterinary oncology study, it was revealed that 45% of dogs reaching the age of 10 or older succumbed to cancer.
Oncology biosimilars are a subset of biosimilar drugs specifically developed to treat cancer. Biosimilars are biologic drugs that closely resemble and exhibit no clinically significant differences from approved reference biologic medications. These reference biologics are typically complex molecules, often used to treat various types of cancer.
The primary objective of veterinary cancer therapies is to achieve the complete elimination of cancer cells in pets. Veterinarians assess each case individually and recommend tailored treatments, which may include targeted therapy, combination therapy, or chemotherapy. The choice of treatment modality depends on factors such as the type of cancer, its stage, and its characteristics.
Veterinary surgical oncology is a specialized field within veterinary medicine that focuses on the surgical treatment of cancer in animals. It involves the diagnosis, staging, and surgical removal of cancerous tumors or tissues in pets. Veterinary surgical oncologists are trained to perform complex surgeries to completely remove or reduce cancerous growths and improve the quality of life for affected animals. These specialists work closely with other veterinary professionals, such as medical oncologists and radiation therapists, to provide comprehensive cancer care for pets.
Veterinary oncology treatment refers to the medical interventions and therapies designed to diagnose, manage, and alleviate cancer in animals, primarily pets. This specialized field of veterinary medicine encompasses various approaches and techniques to address cancer in animals, aiming to improve their quality of life and, ideally, achieve remission or a cure.
Integrated veterinary oncology refers to a comprehensive approach to the diagnosis and treatment of cancer in animals that combines various therapeutic modalities and expertise. This approach involves collaboration among different veterinary specialists, including medical oncologists, surgical oncologists, radiation oncologists, and other professionals, to create a customized treatment plan for each patient.
Animal vaccines are biologically prepared substances designed to stimulate an animal's immune system, helping it develop immunity against specific diseases. Animal vaccines play a crucial role in preventing the spread of infectious diseases among animals, improving overall animal health, and ensuring the safety of the food supply in the case of livestock.
| Report Attributes | Details |
|---|---|
| Veterinary Oncology Market Size (2022A) | US$ 230 Million |
| Estimated Market Value (2023E) | US$ 260 Million |
| Forecasted Market Value (2033F) | US$ 800 Million |
| Global Market Growth Rate (2023 to 2033) | 12% CAGR |
| Chemotherapy Segment Share (2023) | 25% |
| Lymphoma Cancer Segment Share (2023) | 39% |
| Canine Market Share (2023) | 26% |
| United States Market Growth Rate (2023 to 2033) | 6% CAGR |
| Asia Pacific Market Growth Rate (2023 to 2033) | 11.5% CAGR |
| North America Market Share (2023) | 45% |
| Key Companies Profiled |
|
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Why Has Veterinary Oncology Become Popular in Recent Times?
“Growing Emphasis on Pet Health across the World”
Expansion of the global market is primarily propelled by several factors, including the increasing incidence of various cancers such as lymphoma, skin cancer, mast cell cancer, and bone cancer in animals. Additionally, there is a growing demand for veterinary oncology therapies, greater financial support from both private and governmental organizations for animal healthcare centers, and an upswing in research and development endeavors focused on pet oncology treatments.
- As reported by the Flint Animal Cancer Center in 2020, approximately 85% of bone tumors were diagnosed in canine animals, underscoring the significance of this issue.
Furthermore, the surge in pet adoption has the potential to stimulate the growth of the infectious disease diagnostics market.
- Data from the American Veterinary Medical Association in January 2021 indicated a notable increase in the number of new pets per practice, rising from 25% per week in March 2020 to 39% in July 2020.
- Dogs and cats are more susceptible to cancer, as reported by the Journal of the American Animal Hospital Association. This susceptibility underscores the need for advancements in veterinary oncology to address these healthcare challenges effectively.
"Increasing Clinical Investigations into Safety and Effectiveness of Oncological Therapies"
The growing number of veterinary clinical investigations aimed at assessing the safety and effectiveness of various oncological therapies in animals is further catalyzing market expansion. The American Veterinary Medical Association (AVMA) has established the AVMA Animal Health Studies Database (AAHSD), a valuable resource for researchers conducting prospective veterinary clinical studies. Such studies, particularly in the realm of veterinary oncology treatment, are expected to drive market growth in the foreseeable future. The market is being propelled by supportive government initiatives related to veterinary cancer care.
- In July 2019, the National Cancer Institute (NCI) endorsed clinical trials to evaluate oncology treatments for animals. These trials, conducted in veterinary medical schools globally, aimed to discover new cancer treatments that enhance the quality of life for dogs. Moreover, they provided insights into how the veterinary oncology treatments and strategies being examined in dogs could be adapted to benefit people with cancer, given the similarities in the biology of cancer between humans and dogs.
What Obstacles Do Veterinary Oncology Treatment Providers Encounter?
“High Cost of Treatment and Limited Access to Specialized Care”
Cancer treatments in animals can be expensive, and this cost can be a significant barrier for pet owners. Many pet owners may not be able to afford advanced cancer therapies, limiting the accessibility of these treatments. Access to specialized veterinary oncology care may be limited in certain regions, leading to disparities in the quality of care available to pets with cancer.
While cancer treatments aim to improve pets’ health, they can also cause adverse effects and reduce pets’ quality of life. This can lead to difficult decisions for pet owners.
“Lack of Owner Compliance and Ethical and Moral Dilemmas”
Older pets or those with existing health issues may not be good candidates for aggressive cancer treatments, which can limit the treatment options available. Successful cancer treatment often requires strict adherence to treatment plans and follow-up care by pet owners. Lack of owner compliance can hinder the effectiveness of treatment.
Pet owners and veterinarians may face ethical and moral dilemmas when deciding on the appropriate course of treatment for pets with cancer, especially in cases where the prognosis is poor. Compared to human oncology, veterinary oncology has relatively limited research funding and clinical trials. This can slow down the development of new treatments and therapies.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Country-wise Insights
The subsequent section offers a perspective on market revenue categorized by prominent countries, with the United States and China prominently emerging as leaders. According to the analysis conducted by Fact.MR, these countries distinctly represent significant regional prospects among those assessed in the report.
What Lies Ahead for Veterinary Oncology in the United States?
“Growing Animal Population and Increased Government Funding for Oncology Treatment”
Over the period from 2023 to 2030, the market in the United States is projected to advance at a CAGR of 6%.
The North American veterinary oncology market has consistently maintained a substantial share and is projected to sustain this trend throughout the forecast period. This enduring dominance can be ascribed to several factors, including encompassing pets, a growing burden of cancer cases, availability of superior veterinary care and services, and the escalating expenditure on veterinary healthcare within the region.
- On February 27, 2020, Zoetis Inc. secured approval from the United States Food and Drug Administration (FDA) for its medication Tanovea-CA1 (rabacfosadine for injection) designed for the treatment of lymphoma in dogs. This approval marks a significant expansion of the company's oncology product range.
The United States is anticipated to hold a substantial portion of the veterinary oncology market. This is attributable to the country's large animal population, elevated expenditure on animal drug compounding, and a notable prevalence of animal cancer cases.
- In 2023, North America dominated the global market, accounting for a substantial 45% of veterinary oncology market share.
Key factors driving veterinary oncology market growth include growing emphasis on pet healthcare, presence of several pet pharmaceutical manufacturers, and rapid adoption of advanced pet care medications. Additionally, increased government funding for pet oncology treatment in this region, along with the presence of industry leaders in the oncology market, is contributing to market expansion.
What Does the Future Hold for Veterinary Oncology in China?
"High Demand for Oncology Treatments Due to Increasing Prevalence of Cancer among Pets"
The Asia Pacific market is predicted to grow at a fast pace, due to rising pet adoption demand, an increase in the prevalence of canine cancer, and the presence of several veterinary foundations in the region. In the Asia Pacific region, growing awareness among veterinarians regarding diverse pet treatment approaches, enhancements in veterinary healthcare infrastructure, and an upward trend in animal healthcare expenditure are driving market growth.
Growing awareness of animal health and well-being, surging rates of pet adoption, and individual’s increasing disposable income are influencing the demand for pet treatments. In China, the rate of pet ownership is experiencing a rapid surge. Furthermore, the country boasts a substantial patient base due to the significant number of livestock animals, and the rising incidence of cancer among these animals is also anticipated to boost market revenue in this region.
The Asia Pacific region is expected to exhibit substantial growth, driven by a heightened emphasis on animal health and expenditure, a rising pet population susceptible to cancer, government initiatives for animal welfare, and efforts to reduce cancer cases in pets.
Category-wise Insights
The canine segment and chemotherapy occupy 26% and 25% share of the market, respectively, in 2023 According to Fact.MR's assessment, these segments are well-positioned to provide favorable opportunities across all the specified categories in the report.
Why Does Most Revenue Come from the Canine Segment?
"Elevated Cancer Incidence in Canines and Need for Their Extended Life Expectancy"
In 2023, the canine segment accounts for 26% of global veterinary oncology market share. The veterinary oncology market was primarily dominated by the canine segment in 2022, mainly due to the elevated incidence of cancer among canines and their extended life expectancy. This has prompted extensive research involving comparative veterinary oncology treatments, including a significant number of clinical trials using canines as a biological model.
The canine segment is positioned to assert its dominance in the veterinary oncology market, driven by the significant prevalence of cancer in dogs, rising rates of pet adoption, and the extended lifespans of canines, which elevate the likelihood of cancer occurrence.
- According to a March 2021 Frontiers article, cancer ranks as the primary cause of mortality in dogs, primarily due to the frequent diagnosis of advanced-stage cases characterized by unfavorable prognoses and evident clinical symptoms.
What’s Driving Increasing Use of Chemotherapy in Veterinary Oncology?
“Diverse Chemotherapy Approaches Fueling Widespread Treatment Adoption”
In 2023, the chemotherapy sector accounts for a leading portion at 25% of the global veterinary oncology market share.
- According to the guidelines on oncology provided by AAHA, chemotherapy stands as a commonly employed treatment approach within veterinary cancer medicine.
Various chemotherapy methods, including conventional, metronomic, and targeted chemotherapy like tyrosine kinase inhibitors (TKIs), are adopted by small animal practitioners. Consequently, increasing adoption of chemotherapy as a cancer treatment modality for pets is poised to propel the veterinary oncology market growth.
Following chemotherapy, radiology treatment gains prominence, attributed to the growing number of research studies aimed at assessing the safety and effectiveness of stereotactic radiosurgery treatment (SRT) in animals. SRT plays a vital role in controlling tumor growth to a certain extent and subsequently reducing its toxicity.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Competitive Landscape
With many renowned pharmaceutical and medical device companies providing cancer treatments for animal use, the veterinary oncology industry is facing fierce competition. Market players are implementing innovative tactics, such as regional growth, mergers, acquisitions, launch of new products, collaborations, and distribution agreements, all to increase their market share and forge a substantial presence.
- In May 2022, Jaguar Health introduced "Canine Cancer: Take C.H.A.R.G.E." (Canine Health And Registry Exchange), a nationwide canine cancer registry designed to furnish essential incidence and prevalence data to support veterinary professionals and dog owners in making informed decisions regarding the diagnosis and treatment of canine cancer.
Key Segments of Veterinary Oncology Industry Research
-
By Therapy :
- Radiology
- Chemotherapy
- Combination Therapy
- Immunotherapy
- Targeted Therapy
-
By Mode of Administration :
- Oral
- Intravenous
-
By Cancer Type :
- Lymphoma
- Mast Cells
- Mammary & Squamous Cells
-
By Animal Type :
- Canine
- Feline
-
By Distribution Channel :
- Hospital Pharmacies
- Government Agencies
- Retail Pharmacies
-
By Region :
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
Table of Content
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 4. Market Background 4.1. Macro-Economic Factors 4.1.1. Rise in Expenditure 4.1.2. Increased Per Capita Expenditure 4.2. Forecast Factors - Relevance & Impact 4.2.1. Product in Pipeline 4.2.2. Regulatory Scenario 4.2.3. Mergers and Acquisitions 4.2.4. Collaborative Agreements 4.2.5. Value Chain 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunity Analysis 4.4. COVID19 Crisis Analysis 4.4.1. Current COVID19 Statistics and Probable Future Impact 4.4.2. Current GDP Projection and Probable Impact 4.4.3. Current Economic Projection as Compared to 2008 Economic analysis 4.4.4. COVID19 and Impact Analysis 4.4.4.1. Revenue By Therapy 4.4.4.2. Revenue By Cancer Type 4.4.4.3. Revenue By Mode of Administration 4.4.4.4. Revenue By Animal Type 4.4.4.5. Revenue By Distribution Channel 4.4.4.6. Revenue By Country 4.4.5. 2020 Market Scenario 4.4.6. Quarter by Quarter Forecast 4.4.7. Projected Recovery Quarter 4.4.8. Recovery Scenario – Short term, Midterm and Long Term Impact 5. Market Context 5.1. Adoption and Usage Analysis 5.2. Market Evolution 5.3. Product Vs Cancer Type Matrix 5.4. Regulatory Scenario 5.5. Parent Market Analysis 5.6. Key Promotional Strategies by Market Players 6. Global Market - Pricing Analysis 6.1. Regional Pricing Analysis By Therapy 6.2. Pricing Break-up 6.2.1. Manufacturer Level Pricing 6.2.2. Distributor Level Pricing 6.3. Global Average Pricing Analysis Benchmark 7. Global Market Value Analysis 2018 to 2022 and Forecast, 2023 to 2033 7.1. Historical Market Value (US$ Mn) Analysis, 2018 to 2022 7.2. Current and Future Market Value (US$ Mn) Projections, 2023 to 2033 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Mn) Analysis By Therapy, 2018 to 2022 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Therapy, 2023 to 2033 8.3.1. Radiology 8.3.2. Chemotherapy 8.3.3. Combination Therapy 8.3.4. Immunotherapy 8.3.5. Targeted Therapy 8.4. Market Attractiveness Analysis By Therapy 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, by Mode of Administration 9.1. Introduction / Key Findings Nature Size, 2018 to 2022 9.2. Current and Future Market Size (US$ Mn) Analysis and Forecast By Mode of Administration, 2023 to 2033 9.2.1. Oral 9.2.2. Intravenous 9.3. Market Attractiveness Analysis By Mode of Administration 10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, by Cancer Type 10.1. Introduction / Key Findings Cancer Type Size, 2018 to 2022 10.2. Current and Future Market Size (US$ Mn) Analysis and Forecast By Cancer Type, 2023 to 2033 10.2.1. Lymphoma 10.2.2. Mast Cells 10.2.3. Mammary & Squamous Cells 10.3. Market Attractiveness Analysis By Cancer Type 11. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, by Animal Type 11.1. Introduction / Key Findings Size, 2018 to 2022 11.2. Current and Future Market Size (US$ Mn) Analysis and Forecast By Animal Type, 2023 to 2033 11.2.1. Canine 11.2.2. Feline 11.3. Market Attractiveness Analysis By Animal Type 12. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, by Distribution Channel 12.1. Introduction / Key Findings 12.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2018 to 2022 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2023 to 2033 12.3.1. Hospital Pharmacies 12.3.2. Government Agencies 12.3.3. Retail Pharmacies 12.4. Market Attractiveness Analysis By Distribution Channel 13. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, by Region 13.1. Introduction 13.2. Historical Market Size (US$ Mn) Analysis By Region, 2018 to 2022 13.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2023 to 2033 13.3.1. North America 13.3.2. Latin America 13.3.3. Europe 13.3.4. East Asia 13.3.5. South Asia 13.3.6. Oceania 13.3.7. Middle East and Africa (MEA) 13.4. Market Attractiveness Analysis By Region 14. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 14.1. Introduction 14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2022 14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023 to 2033 14.3.1. By Country 14.3.1.1. United States 14.3.1.2. Canada 14.3.2. By Therapy 14.3.3. By Nature 14.3.4. By Cancer Type 14.3.5. By Animal Type 14.3.6. By Distribution Channel 14.4. Market Attractiveness Analysis 14.5. Market Trends 14.6. Key Market Participants - Intensity Mapping 14.7. Drivers and Restraints - Impact Analysis 15. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033 15.1. Introduction 15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2022 15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023 to 2033 15.3.1. By Country 15.3.1.1. Germany 15.3.1.2. Italy 15.3.1.3. France 15.3.1.4. United Kingdom 15.3.1.5. Spain 15.3.1.6. Rest of Europe 15.3.2. By Therapy 15.3.3. By Nature 15.3.4. By Cancer Type 15.3.5. By Animal Type 15.3.6. By Distribution Channel 15.4. Market Attractiveness Analysis 15.5. Market Trends 15.6. Key Market Participants - Intensity Mapping 15.7. Drivers and Restraints - Impact Analysis 16. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033 16.1. Introduction 16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2022 16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023 to 2033 16.3.1. By Country 16.3.1.1. GCC Countries 16.3.1.2. South Africa 16.3.1.3. Rest of Middle East and Africa 16.3.2. By Therapy 16.3.3. By Nature 16.3.4. By Cancer Type 16.3.5. By Animal Type 16.3.6. By Distribution Channel 16.4. Market Attractiveness Analysis 16.5. Market Trends 16.6. Key Market Participants - Intensity Mapping 16.7. Drivers and Restraints - Impact Analysis 17. Rest of the World Market Analysis 2018 to 2022 and Forecast 2023 to 2033 17.1. Introduction 17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2022 17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023 to 2033 17.3.1. By Therapy 17.3.2. By Mode of Administration 17.3.3. By Cancer Type 17.3.4. By Animal Type 17.3.5. By Distribution Channel 17.4. Market Attractiveness Analysis 17.5. Market Trends 17.6. Key Market Participants - Intensity Mapping 17.7. Drivers and Restraints - Impact Analysis 18. Key and Emerging Countries Market Analysis 2018 to 2022 and Forecast 2023 to 2033 18.1. Introduction 18.1.1. Market Value Proportion Analysis, By Key Countries 18.1.2. Global Vs. Country Growth Comparison 18.2. United States Market Analysis 18.2.1. By Therapy 18.2.2. By Mode of Administration 18.2.3. By Cancer Type 18.2.4. By Animal Type 18.2.5. By Distribution Channel 18.3. Canada Market Analysis 18.3.1. By Therapy 18.3.2. By Mode of Administration 18.3.3. By Cancer Type 18.3.4. By Animal Type 18.3.5. By Distribution Channel 18.4. United Kingdom Market Analysis 18.4.1. By Therapy 18.4.2. By Mode of Administration 18.4.3. By Cancer Type 18.4.4. By Animal Type 18.4.5. By Distribution Channel 18.5. Germany Market Analysis 18.5.1. By Therapy 18.5.2. By Mode of Administration 18.5.3. By Cancer Type 18.5.4. By Animal Type 18.5.5. By Distribution Channel 18.6. France Market Analysis 18.6.1. By Therapy 18.6.2. By Mode of Administration 18.6.3. By Cancer Type 18.6.4. By Animal Type 18.6.5. By Distribution Channel 18.7. Italy Market Analysis 18.7.1. By Therapy 18.7.2. By Mode of Administration 18.7.3. By Cancer Type 18.7.4. By Animal Type 18.7.5. By Distribution Channel 18.8. Spain Market Analysis 18.8.1. By Therapy 18.8.2. By Mode of Administration 18.8.3. By Cancer Type 18.8.4. By Animal Type 18.8.5. By Distribution Channel 18.8.6. By Distribution Channel 18.9. GCC Countries Market Analysis 18.9.1. By Therapy 18.9.2. By Mode of Administration 18.9.3. By Cancer Type 18.9.4. By Animal Type 18.9.5. By Distribution Channel 18.10. South Africa Market Analysis 18.10.1. By Therapy 18.10.2. By Mode of Administration 18.10.3. By Cancer Type 18.10.4. By Animal Type 18.10.5. By Distribution Channel 19. Market Structure Analysis 19.1. Market Analysis by Tier of Companies 19.2. Market Concentration 19.3. Market Share Analysis of Top Players 19.4. Market Presence Analysis 19.4.1. By Regional footprint of Players 19.4.2. Product foot print by Players 19.4.3. Channel Foot Print by Players 20. Competition Analysis 20.1. Competition Dashboard 20.2. Competition Benchmarking 20.3. Competition Deep Dive 20.3.1. Elanco 20.3.1.1. Overview 20.3.1.2. Product Portfolio 20.3.1.3. Analyst Commentary 20.3.1.4. Key Financials 20.3.1.5. Recent Developments 20.3.1.6. Sales Footprint 20.3.1.7. Strategy Overview 20.3.1.7.1. Marketing Strategy 20.3.1.7.2. Product Strategy 20.3.1.7.3. Channel Strategy 20.3.2. Morphogenesis 20.3.2.1. Overview 20.3.2.2. Product Portfolio 20.3.2.3. Analyst Commentary 20.3.2.4. Key Financials 20.3.2.5. Recent Developments 20.3.2.6. Sales Footprint 20.3.2.7. Strategy Overview 20.3.2.7.1. Marketing Strategy 20.3.2.7.2. Product Strategy 20.3.2.7.3. Channel Strategy 20.3.3. Accuray Incorporated 20.3.3.1. Overview 20.3.3.2. Product Portfolio 20.3.3.3. Analyst Commentary 20.3.3.4. Key Financials 20.3.3.5. Recent Developments 20.3.3.6. Sales Footprint 20.3.3.7. Strategy Overview 20.3.3.7.1. Marketing Strategy 20.3.3.7.2. Product Strategy 20.3.3.7.3. Channel Strategy 20.3.4. Regeneus Ltd. 20.3.4.1. Overview 20.3.4.2. Product Portfolio 20.3.4.3. Analyst Commentary 20.3.4.4. Key Financials 20.3.4.5. Recent Developments 20.3.4.6. Sales Footprint 20.3.4.7. Strategy Overview 20.3.4.7.1. Marketing Strategy 20.3.4.7.2. Product Strategy 20.3.4.7.3. Channel Strategy 20.3.5. PetCure Oncology 20.3.5.1. Overview 20.3.5.2. Product Portfolio 20.3.5.3. Analyst Commentary 20.3.5.4. Key Financials 20.3.5.5. Recent Developments 20.3.5.6. Sales Footprint 20.3.5.7. Strategy Overview 20.3.5.7.1. Marketing Strategy 20.3.5.7.2. Product Strategy 20.3.5.7.3. Channel Strategy 20.3.6. Zoetis 20.3.6.1. Overview 20.3.6.2. Product Portfolio 20.3.6.3. Analyst Commentary 20.3.6.4. Key Financials 20.3.6.5. Recent Developments 20.3.6.6. Sales Footprint 20.3.6.7. Strategy Overview 20.3.6.7.1. Marketing Strategy 20.3.6.7.2. Product Strategy 20.3.6.7.3. Channel Strategy 20.3.7. Karyopharm 20.3.7.1. Overview 20.3.7.2. Product Portfolio 20.3.7.3. Analyst Commentary 20.3.7.4. Key Financials 20.3.7.5. Recent Developments 20.3.7.6. Sales Footprint 20.3.7.7. Strategy Overview 20.3.7.7.1. Marketing Strategy 20.3.7.7.2. Product Strategy 20.3.7.7.3. Channel Strategy 20.3.8. Varian Medical Systems, Inc. 20.3.8.1. Overview 20.3.8.2. Product Portfolio 20.3.8.3. Analyst Commentary 20.3.8.4. Key Financials 20.3.8.5. Recent Developments 20.3.8.6. Sales Footprint 20.3.8.7. Strategy Overview 20.3.8.7.1. Marketing Strategy 20.3.8.7.2. Product Strategy 20.3.8.7.3. Channel Strategy 20.3.9. OHC (One Health Company) 20.3.9.1. Overview 20.3.9.2. Product Portfolio 20.3.9.3. Analyst Commentary 20.3.9.4. Key Financials 20.3.9.5. Recent Developments 20.3.9.6. Sales Footprint 20.3.9.7. Strategy Overview 20.3.9.7.1. Marketing Strategy 20.3.9.7.2. Product Strategy 20.3.9.7.3. Channel Strategy 21. Assumptions and Acronyms Used 22. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy
Table 02: Global Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Mode of Administration
Table 03: Global Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Cancer Type
Table 04: Global Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Animal Type
Table 05: Global Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
Table 06: Global Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Animal Type Age Group
Table 07: Global Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
Table 08: North America Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
Table 09: North America Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy
Table 10: North America Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Cancer Type
Table 11: North America Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Mode of Administration
Table 12: North America Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Animal Type
Table 13: North America Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
Table 14: Europe Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
Table 15: Europe Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy
Table 16: Europe Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Cancer Type
Table 17: Europe Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Mode of Administration
Table 18: Europe Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Animal Type
Table 19: Europe Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
Table 20: Middle East and Africa Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
Table 21: Middle East and Africa Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy
Table 22: Middle East and Africa Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Cancer Type
Table 23: Middle East and Africa Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Mode of Administration
Table 24: Middle East and Africa Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Animal Type
Table 25: Middle East and Africa Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
Table 26: Rest of the World Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy
Table 27: Rest of the World Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Cancer Type
Table 28: Rest of the World Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Mode of Administration
Table 29: Rest of the World Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Animal Type
Table 30: Rest of the World Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Value (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033
Figure 02: Global Market Absolute $ Opportunity, 2023 to 2033
Figure 03: Global Market Share Analysis (%), By Therapy, 2023 & 2033
Figure 04: Global Market Y-o-Y Analysis (%), By Therapy, 2023 to 2033
Figure 05: Global Market Attractiveness Analysis By Therapy, 2023 to 2033
Figure 06: Global Market Share Analysis (%), By Mode of Administration, 2023 & 2033
Figure 07: Global Market Y-o-Y Analysis (%), By Mode of Administration, 2023 to 2033
Figure 08: Global Market Attractiveness Analysis By Mode of Administration, 2023 to 2033
Figure 09: Global Market Share Analysis (%), By Cancer Type, 2023 & 2033
Figure 10: Global Market Y-o-Y Analysis (%), By Cancer Type, 2023 to 2033
Figure 11: Global Market Attractiveness Analysis By Cancer Type, 2023 to 2033
Figure 12: Global Market Share Analysis (%), By Animal Type, 2023 & 2033
Figure 13: Global Market Y-o-Y Analysis (%), By Animal Type, 2023 to 2033
Figure 14: Global Market Attractiveness Analysis By Animal Type, 2023 to 2033
Figure 15: Global Market Share Analysis (%), By Distribution Channel, 2023 & 2033
Figure 16: Global Market Y-o-Y Analysis (%), By Distribution Channel , 2023 to 2033
Figure 17: Global Market Attractiveness Analysis, By Distribution Channel, 2023 to 2033
Figure 18: Global Market Share Analysis (%), By Animal Type Age Group, 2023 & 2033
Figure 19: Global Market Y-o-Y Analysis (%), By Animal Type Age Group, 2023 to 2033
Figure 20: Global Market Attractiveness Analysis By Animal Type Age Group, 2023 to 2033
Figure 21: Global Market Share Analysis (%), By Region, 2023 & 2033
Figure 22: Global Market Y-o-Y Analysis (%), By Region, 2023 to 2033
Figure 23: Global Market Attractiveness Analysis, By Region, 2023 to 2033
Figure 24: North America Market Value Share, By Therapy, 2023 (E)
Figure 25: North America Market Value Share, By Cancer Types 2023 (E)
Figure 26: North America Market Value Share, By Mode of Administration, 2023 (E)
Figure 27: North America Market Value Share, By Animal Type, 2023 (E)
Figure 28: North America Market Value Share, By Distribution Channel, 2023 (E)
Figure 29: North America Market Value Share, By Country, 2023 (E)
Figure 30: North America Market Value (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033
Figure 31: North America Market Attractiveness Analysis By Therapy, 2023 to 2033
Figure 32: North America Market Attractiveness Analysis By Cancer Type, 2023 to 2033
Figure 33: North America Market Attractiveness Analysis By Mode of Administration, 2023 to 2033
Figure 34: North America Market Attractiveness Analysis By Animal Type, 2023 to 2033
Figure 35: North America Market Attractiveness Analysis By Distribution Channel, 2023 to 2033
Figure 36: North America Market Attractiveness Analysis By Country, 2023 to 2033
Figure 37: Europe Market Value Share, By Therapy, 2023 (E)
Figure 38: Europe Market Value Share, By Cancer Types 2023 (E)
Figure 39: Europe Market Value Share, By Mode of Administration, 2023 (E)
Figure 40: Europe Market Value Share, By Animal Type, 2023 (E)
Figure 41: Europe Market Value Share, By Distribution Channel, 2023 (E)
Figure 42: Europe Market Value Share, By Country, 2023 (E)
Figure 43: Europe Market Value (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033
Figure 44: Europe Market Attractiveness Analysis By Therapy, 2023 to 2033
Figure 45: Europe Market Attractiveness Analysis By Cancer Type, 2023 to 2033
Figure 46: Europe Market Attractiveness Analysis By Mode of Administration, 2023 to 2033
Figure 47: Europe Market Attractiveness Analysis By Animal Type, 2023 to 2033
Figure 48: Europe Market Attractiveness Analysis By Mode of Administration, 2023 to 2033
Figure 49: Europe Market Attractiveness Analysis By Country, 2023 to 2033
Figure 50: Middle East and Africa Market Value Share, By Therapy, 2023 (E)
Figure 51: Middle East and Africa Market Value Share, By Cancer Type, 2023 (E)
Figure 52: Middle East and Africa Market Value Share, By Mode of Administration, 2023 (E)
Figure 53: Middle East and Africa Market Value Share, By Animal Type, 2023 (E)
Figure 54: Middle East and Africa Market Value Share, By Distribution Channel, 2023 (E)
Figure 55: Middle East and Africa Market Value Share, By Country, 2023 (E)
Figure 56: Middle East and Africa Market Value (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033
Figure 57: Middle East and Africa Market Attractiveness Analysis By Therapy, 2023 to 2033
Figure 58: Middle East and Africa Market Attractiveness Analysis By Cancer Type, 2023 to 2033
Figure 59: Middle East and Africa Market Attractiveness Analysis By Mode of Administration, 2023 to 2033
Figure 60: Middle East and Africa Market Attractiveness Analysis By Animal Type, 2023 to 2033
Figure 61: Middle East and Africa Market Attractiveness Analysis By Distribution Channel, 2023 to 2033
Figure 62: Middle East and Africa Market Attractiveness Analysis By Country, 2023 to 2033
Figure 63: Rest of the World Market Value Share, By Therapy, 2023 (E)
Figure 64: Rest of the World Market Value Share, By Cancer Types 2023 (E)
Figure 65: Rest of the World Market Value Share, By Mode of Administration, 2023 (E)
Figure 66: Rest of the World Market Value Share, By Animal Type, 2023 (E)
Figure 67: Rest of the World Market Value Share, By Distribution Channel, 2023 (E)
Figure 68: Rest of the World Market Value (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033
Figure 69: Rest of the World Market Attractiveness Analysis By Therapy, 2023 to 2033
Figure 70: Rest of the World Market Attractiveness Analysis By Cancer Type, 2023 to 2033
Figure 71: Rest of the World Market Attractiveness Analysis By Mode of Administration, 2023 to 2033
Figure 72: Rest of the World Market Attractiveness Analysis By Animal Type, 2023 to 2033
Figure 73: Rest of the World Market Attractiveness Analysis By Distribution Channel, 2023 to 2033
Figure 74: United States Market Value Share, By Therapy, 2023 & 2033
Figure 75: United States Market Value Share, By Cancer Type, 2023 & 2033
Figure 76: United States Market Value Share, By Mode of Administration, 2020 &2030
Figure 77: United States Market Value Share, By Animal Type Age Group, 2023 & 2033
Figure 78: United States Market Value Share, By Distribution Channel, 2023 & 2033
Figure 79: United States Market Value Analysis (US$ Mn), 2023 & 2033
Figure 80: Canada Market Value Share, By Therapy, 2023 & 2033
Figure 81: Canada Market Value Share, By Cancer Type, 2023 & 2033
Figure 82: Canada Market Value Share, By Mode of Administration, 2023 & 2033
Figure 83: Canada Market Value Share, By Animal Type Age Group, 2023 & 2033
Figure 84: Canada Market Value Share, By Distribution Channel, 2023 & 2033
Figure 85: Canada Market Value Analysis (US$ Mn), 2023 & 2033
Figure 86: United Kingdom Market Value Share, By Therapy, 2023 & 2033
Figure 87: United Kingdom Market Value Share, By Cancer Type, 2023 & 2033
Figure 88: United Kingdom Market Value Share, By Mode of Administration, 2023 & 2033
Figure 89: United Kingdom Market Value Share, By Animal Type Age Group, 2023 & 2033
Figure 90: United Kingdom Market Value Share, By Distribution Channel, 2023 & 2033
Figure 91: United Kingdom Market Value Analysis (US$ Mn), 2023 & 2033
Figure 92: Germany Market Value Share, By Therapy, 2023 & 2033
Figure 93: Germany Market Value Share, By Cancer Type, 2023 & 2033
Figure 94: Germany Market Value Share, By Mode of Administration, 2023 & 2033
Figure 95: Germany Market Value Share, By Animal Type Age Group, 2023 & 2033
Figure 96: Germany Market Value Share, By Distribution Channel, 2023 & 2033
Figure 97: Germany Market Value Analysis (US$ Mn), 2023 & 2033
Figure 98: France Market Value Share, By Therapy, 2023 & 2033
Figure 99: France Market Value Share, By Cancer Type, 2023 & 2033
Figure 100: France Market Value Share, By Mode of Administration, 2023 & 2033
Figure 101: France. Market Value Share, By Animal Type Age Group, 2023 & 2033
Figure 102: France Market Value Share, By Distribution Channel, 2023 & 2033
Figure 103: France Market Value Analysis (US$ Mn), 2023 & 2033
Figure 104: Italy Market Value Share, By Therapy, 2023 & 2033
Figure 105: Italy Market Value Share, By Cancer Type, 2023 & 2033
Figure 106: Italy Market Value Share, By Mode of Administration, 2023 & 2033
Figure 107: Italy Market Value Share, By Animal Type Age Group, 2023 & 2033
Figure 108: Italy Market Value Share, By Distribution Channel, 2023 & 2033
Figure 109: Italy Market Value Analysis (US$ Mn), 2023 & 2033
Figure 110: Spain Market Value Share, By Therapy, 2023 & 2033
Figure 111: Spain Market Value Share, By Cancer Type, 2023 & 2033
Figure 112: Spain Market Value Share, By Mode of Administration, 2023 & 2033
Figure 113: Spain Market Value Share, By Animal Type Age Group, 2023 & 2033
Figure 114: Spain Market Value Share, By Distribution Channel, 2023 & 2033
Figure 115: Spain Market Value Analysis (US$ Mn), 2023 & 2033
Figure 116: GCC Countries. Market Value Share, By Therapy, 2023 & 2033
Figure 117: GCC Countries Market Value Share, By Cancer Type, 2023 & 2033
Figure 118: GCC Countries Market Value Share, By Mode of Administration, 2023 & 2033
Figure 119: GCC Countries Market Value Share, By Animal Type, 2023 & 2033
Figure 120: GCC Countries Market Value Share, By Distribution Channel, 2023 & 2033
Figure 121: GCC Countries Market Value Analysis (US$ Mn), 2023 & 2033
Figure 122: South Africa Market Value Share, By Therapy, 2023 & 2033
Figure 123: South Africa Market Value Share, By Cancer Type, 2023 & 2033
Figure 124: South Africa Market Value Share, By Mode of Administration, 2023 & 2033
Figure 125: South Africa Market Value Share, By Animal Type Age Group, 2023 & 2033
Figure 126: South Africa Market Value Share, By Distribution Channel, 2023 & 2033
Figure 127: South Africa Market Value Analysis (US$ Mn), 2023 & 2033
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
How big is the global veterinary oncology market in 2023?
The global veterinary oncology market is valued at US$ 260 million in 2023.
What is the forecasted demand growth for veterinary oncology treatment?
Worldwide demand for veterinary oncology treatment is set to increase at a CAGR of 12% from 2023 to 2033.
What is the growth outlook for veterinary oncology treatment?
Revenue from veterinary oncology treatment is projected to reach US$ 800 million by 2033.
At what rate is the demand for veterinary oncology set to rise in Asia Pacific?
Demand for veterinary oncology is forecasted to increase at a CAGR of 11.5% in Asia Pacific.
What is the expected pace of market growth in the United States?
The market in the United States is set to expand at a CAGR of 6% through 2033.
What is the revenue share held by chemotherapy treatment?
Chemotherapy is projected to account for a market share of 25% in 2023.
Veterinary Oncology Market